ArticleInternational journal of inflammation2026
Quinic and Ferulic Acid-Loaded Chitosan Nanoparticles Attenuate Experimental Ulcerative Colitis by Modulating the IL-32/IL-33/IL-34 Axis and NF-κB Signaling.
Article in International journal of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quinic and Ferulic Acid-Loaded Chitosan Nanoparticles Attenuate Experimental Ulcerative Colitis by Modulating the IL-32/IL-33/IL-34 Axis and NF-κB Signaling.International journal of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ulcerative colitis (UC) is characterized by immune dysregulation and localized inflammation of the colonic mucosa. Despite advances in therapy, effective treatment remains difficult. This study aimed to investigate the immunomodulatory and therapeutic effects of chitosan nanoparticles (CS-NPs) loaded with quinic acid (QA) and ferulic acid (FA) in an experimental model of UC, focusing on the IL-32/IL-33/IL-34 cytokine axis and the NF-κB signaling pathway. Methods: Eighty male Wistar rats were randomly divided into 10 groups ( Results: Induction of UC significantly increased IL-32 protein levels as well as the expression of IL-33, IL-34, and NF-κB. Oral administration with mesalazine, FA/QA/CS-NPs, QA/CS-NPs, FA/CS-NPs, FA/QA, QA, and FA significantly decreased IL-32 protein levels and the expression of IL-33, IL-34, and NF-κB relative to the model group. Conclusion: FA/QA-loaded CS-NPs exhibit anti-inflammatory effects in experimental UC, likely through modulation of the IL-32/IL-33/IL-34 cytokine axis and NF-κB signaling. These findings suggest that FA/QA/CS-NPs may serve as a promising herbal-based therapeutic candidate for the treatment of UC in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.